CLOVER BIO-B (02197) announces mid-term results, with profit attributable to equity holders of the parent company reaching 955 million yuan, turning a profit compared to the previous year.

06:33 26/08/2026

Sanyecao Biotechnology-B (02197) announced its results for the six months ending June 30, 2026. During this period, the group reported revenue of RMB 179,000, a year-on-year decrease of 94.5%; other income and gains amounted to RMB 1.1112 billion, a year-on-year increase of 6200.94%; profit attributable to equity holders of the parent company was RMB 955 million, turning from loss to profit year-on-year; basic earnings per share were RMB 0.75.

CLOVER BIO-B (02197) announced its results for the six months ending June 30, 2026, during which the group generated revenue of 179,000 RMB, a decrease of 94.5% year-on-year; other income and gains amounted to 1.1112 billion RMB, an increase of 6200.94% year-on-year; profit attributable to equity holders of the parent was 955 million RMB, reversing from a loss to a profit; basic earnings per share were 0.75 RMB.

MANULIFE-S (00945) will distribute a second-quarter dividend of CAD 0.485 per share on September 21.

BRETON (01333) expects to incur a loss of approximately 80 million to 90 million yuan in the medium term, narrowing by about 45.93% to 51.67% compared to the same period last year.

AKESO (09926): The AK112309/HARMONi-GI1 Phase III clinical trial achieved statistically significant positive results in overall survival (OS) when comparing the efficacy of Abraxane combined with gemcitabine to that of Atezolizumab combined with chemotherapy, indicating substantial clinical benefits.

MANULIFE-S (00945) will distribute a second-quarter dividend of CAD 0.485 per share on September 21.

BRETON (01333) expects to incur a loss of approximately 80 million to 90 million yuan in the medium term, narrowing by about 45.93% to 51.67% compared to the same period last year.